



Clinical trial results:

A Phase 1, Open-Label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

Summary

EudraCT number	2019-004930-41
Trial protocol	Outside EU/EEA
Global end of trial date	05 July 2019

Results information

Result version number	v1 (current)
This version publication date	27 March 2020
First version publication date	27 March 2020
Summary attachment (see zip file)	Results Summary 9766-CL-0046 Part 1 and Part 2 combined in a row (Results Summary 9766-CL-0046 Part 1 and Part 2 combined in a row.pdf)

Trial information

Trial identification

Sponsor protocol code	9766-CL-0046
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03241550
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Astellas Pharma Global Development, Inc.
Sponsor organisation address	1 Astellas Way, Northbrook, IL, United States, 60062
Public contact	Study Physician, Astellas Pharma Global Development, Inc., 1 2242055223,
Scientific contact	Study Physician, Astellas Pharma Global Development, Inc., 1 2242055223,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001301-PIP02-12
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 July 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 July 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of IV and oral isavuconazonium sulfate administered daily in pediatric patients.
The PK data will be utilized to establish a pediatric population PK model of isavuconazole, the active moiety of isavuconazonium sulfate.

Protection of trial subjects:

The study is performed under carefully controlled conditions. All subjects taking part in the study will be examined thoroughly and regularly for any side effects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 October 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 49
Worldwide total number of subjects	49
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	2
Children (2-11 years)	27
Adolescents (12-17 years)	20
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 54 subjects were screened, out of whom 5 subjects failed screening. Forty-nine subjects were enrolled and 46 subjects received at least one dose.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Age group 1 to < 6 years, intravenous isavuconazonium sulfate

Arm description:

Age group 1 to < 6 years in the Part 1-study: intravenous infusion

Arm type	Experimental
Investigational medicinal product name	Isavuconazonium sulfate for injection
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dose: 10 mg/kg (maximum 372.5 mg) isavuconazonium sulfate as 1-hour intravenous infusion. A dose was given every 8 hours on day 1 and day 2, followed by once-daily dosing for up to 26 additional days.

Arm title	Age group 6 to < 12 years, intravenous isavuconazonium sulfate
------------------	--

Arm description:

Age group 6 to < 12 years in the Part 1-study: intravenous infusion

Arm type	Experimental
Investigational medicinal product name	Isavuconazonium sulfate for injection
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dose: 10 mg/kg (maximum 372.5 mg) isavuconazonium sulfate as 1-hour intravenous infusion. A dose was given every 8 hours on day 1 and day 2, followed by once-daily dosing for up to 26 additional days.

Arm title	Age group 12 to < 18 years, intraven. isavuconazonium sulfate
------------------	---

Arm description:

Age group 12 to < 18 years in the Part 1-study: intravenous infusion

Arm type	Experimental
Investigational medicinal product name	Isavuconazonium sulfate for injection
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dose: 10 mg/kg (maximum 372.5 mg) isavuconazonium sulfate as 1-hour intravenous infusion. A dose was given every 8 hours on day 1 and day 2, followed by once-daily dosing for up to 26 additional days.

Arm title	Age group 6 to < 12 years, oral isavuconazonium sulfate
------------------	---

Arm description:

Age group 6 to < 12 years in the Part 2-study: oral capsule

Arm type	Experimental
Investigational medicinal product name	Isavuconazonium sulfate capsule
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose (body weight): 149 mg (16-17 kg), 223.5 mg (18-24 kg), 298 mg (25-31 kg), 372.5 mg (\geq 32 kg) isavuconazonium sulfate as oral capsules. A dose was given every 8 hours on day 1 and day 2, followed by once-daily dosing for up to 26 additional days.

Arm title	Age group 12 to < 18 years, oral isavuconazonium sulfate
------------------	--

Arm description:

Age group 12 to < 18 years in the Part 2-study: oral capsule

Arm type	Experimental
Investigational medicinal product name	Isavuconazonium sulfate capsule
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Dose (body weight): 149 mg (16-17 kg), 223.5 mg (18-24 kg), 298 mg (25-31 kg), 372.5 mg (\geq 32 kg) isavuconazonium sulfate as oral capsules. A dose was given every 8 hours on day 1 and day 2, followed by once-daily dosing for up to 26 additional days.

Number of subjects in period 1^[1]	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate
Started	9	8	10
Completed	9	7	8
Not completed	0	1	2
Consent withdrawn by subject	-	-	1
Adverse event, non-fatal	-	1	1
Concomitant medication use	-	-	-

Number of subjects in period 1^[1]	Age group 6 to < 12 years, oral isavuconazonium sulfate	Age group 12 to < 18 years, oral isavuconazonium sulfate
Started	9	10
Completed	6	8
Not completed	3	2

Consent withdrawn by subject	-	-
Adverse event, non-fatal	3	1
Concomitant medication use	-	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Reported are subjects who received at least one dose (safety population).

Baseline characteristics

Reporting groups

Reporting group title	Age group 1 to < 6 years, intravenous isavuconazonium sulfate
Reporting group description:	
Age group 1 to < 6 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 6 to < 12 years, intravenous isavuconazonium sulfate
Reporting group description:	
Age group 6 to < 12 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 12 to < 18 years, intraven. isavuconazonium sulfate
Reporting group description:	
Age group 12 to < 18 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 6 to < 12 years, oral isavuconazonium sulfate
Reporting group description:	
Age group 6 to < 12 years in the Part 2-study: oral capsule	
Reporting group title	Age group 12 to < 18 years, oral isavuconazonium sulfate
Reporting group description:	
Age group 12 to < 18 years in the Part 2-study: oral capsule	

Reporting group values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate
Number of subjects	9	8	10
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	1	0	0
Children (2-11 years)	8	8	0
Adolescents (12-17 years)	0	0	10
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	3.3	9.0	14.6
standard deviation	± 1.1	± 1.7	± 1.8
Gender categorical			
Units: Subjects			
Female	3	2	2
Male	6	6	8
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	6	6	5
Hispanic or Latino	3	2	4
Missing	0	0	1

Race			
Units: Subjects			
White	5	7	6
Black or African American	2	1	1
Asian	1	0	1
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	1	0	0
Other	0	0	2

Reporting group values	Age group 6 to < 12 years, oral isavuconazonium sulfate	Age group 12 to < 18 years, oral isavuconazonium sulfate	Total
Number of subjects	9	10	46
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	1
Children (2-11 years)	9	0	25
Adolescents (12-17 years)	0	10	20
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	9.0	14.5	
standard deviation	± 1.9	± 1.4	-
Gender categorical			
Units: Subjects			
Female	4	6	17
Male	5	4	29
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	2	8	27
Hispanic or Latino	7	2	18
Missing	0	0	1
Race			
Units: Subjects			
White	8	7	33
Black or African American	0	1	5
Asian	0	1	3
American Indian or Alaska Native	1	0	1
Native Hawaiian or Other Pacific Islander	0	0	1
Other	0	1	3

End points

End points reporting groups

Reporting group title	Age group 1 to < 6 years, intravenous isavuconazonium sulfate
Reporting group description:	
Age group 1 to < 6 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 6 to < 12 years, intravenous isavuconazonium sulfate
Reporting group description:	
Age group 6 to < 12 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 12 to < 18 years, intraven. isavuconazonium sulfate
Reporting group description:	
Age group 12 to < 18 years in the Part 1-study: intravenous infusion	
Reporting group title	Age group 6 to < 12 years, oral isavuconazonium sulfate
Reporting group description:	
Age group 6 to < 12 years in the Part 2-study: oral capsule	
Reporting group title	Age group 12 to < 18 years, oral isavuconazonium sulfate
Reporting group description:	
Age group 12 to < 18 years in the Part 2-study: oral capsule	

Primary: Cmax D3 iv (Part 1 only)

End point title	Cmax D3 iv (Part 1 only) ^{[1][2]}
End point description:	
Maximum observed drug concentration (Cmax) in plasma of intravenous isavuconazole	
End point type	Primary
End point timeframe:	
Day 3	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint reports the Cmax on D3 of isavuconazole for the IV dose only.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	6	8	
Units: ng/ml				
arithmetic mean (standard deviation)	7810 (± 830)	7800 (± 1640)	5530 (± 2320)	

Statistical analyses

No statistical analyses for this end point

Primary: Ctrough D3 iv and oral (Part 1 and Part 2)

End point title	Ctrough D3 iv and oral (Part 1 and Part 2) ^[3]
End point description: Lowest concentration in plasma (Ctrough) of intravenous and oral isavuconazole reached before administration of the next dose, measured on Day3	
End point type	Primary
End point timeframe: D3	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	Age group 6 to < 12 years, oral isavuconazonium sulfate
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	9	9
Units: ng/ml				
arithmetic mean (standard deviation)	4200 (± 1440)	4310 (± 2120)	2520 (± 1120)	4660 (± 2420)

End point values	Age group 12 to < 18 years, oral isavuconazonium sulfate			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: ng/ml				
arithmetic mean (standard deviation)	3690 (± 1900)			

Statistical analyses

No statistical analyses for this end point

Primary: AUCtau D3 iv (Part 1 only)

End point title	AUCtau D3 iv (Part 1 only) ^{[4][5]}
End point description: Area under the plasma concentration time curve over dosing interval (AUCtau) of intravenous isavuconazole, measured on Day3	
End point type	Primary
End point timeframe: D3	

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint reports the AUCtau on D3 of isavuconazole for the IV dose only.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	6	8	
Units: h*ng/ml				
arithmetic mean (standard deviation)	112000 (± 25000)	102000 (± 35000)	70100 (± 29600)	

Statistical analyses

No statistical analyses for this end point

Primary: tmax D3 iv (Part 1 only)

End point title	tmax D3 iv (Part 1 only) ^{[6][7]}
End point description:	Time to reach peak plasma concentration (tmax) of intravenous isavuconazole, measured on D3
End point type	Primary
End point timeframe:	D3

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint reports the tmax on Day 3 of isavuconazole for the IV dose only

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	6	8	
Units: hours				
median (full range (min-max))	1.11 (0.883 to 1.17)	1.08 (1.02 to 4.37)	1.11 (0.900 to 1.17)	

Statistical analyses

No statistical analyses for this end point

Primary: Cmax D7 iv and oral (Part 1 and Part 2)

End point title	Cmax D7 iv and oral (Part 1 and Part 2) ^[8]
End point description:	Maximum observed drug concentration (Cmax) in plasma of intravenous and oral isavuconazole
End point type	Primary
End point timeframe:	D7

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	Age group 6 to < 12 years, oral isavuconazonium sulfate
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	7	9
Units: ng/ml				
arithmetic mean (standard deviation)	7310 (± 1210)	6780 (± 2110)	5020 (± 1200)	6040 (± 2240)

End point values	Age group 12 to < 18 years, oral isavuconazonium sulfate			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: ng/ml				
arithmetic mean (standard deviation)	5030 (± 2170)			

Statistical analyses

No statistical analyses for this end point

Primary: AUCtau D7 iv and oral (Part 1 and Part 2)

End point title	AUCtau D7 iv and oral (Part 1 and Part 2) ^[9]
End point description:	Area under the plasma concentration time curve over dosing interval (AUCtau) of intravenous and oral isavuconazole, measured on Day7
End point type	Primary
End point timeframe:	D7

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	Age group 6 to < 12 years, oral isavuconazonium sulfate
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	8	6	7
Units: h*ng/ml				
arithmetic mean (standard deviation)	96800 (± 47300)	87200 (± 33200)	76800 (± 20500)	111000 (± 50200)

End point values	Age group 12 to < 18 years, oral isavuconazonium sulfate			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: h*ng/ml				
arithmetic mean (standard deviation)	83300 (± 33400)			

Statistical analyses

No statistical analyses for this end point

Primary: tmax D7 iv and oral (Part 1 and Part 2)

End point title	tmax D7 iv and oral (Part 1 and Part 2) ^[10]
End point description: Time to reach peak plasma concentration (tmax) of intravenous and oral isavuconazole, measured on D3	
End point type	Primary
End point timeframe: D7	

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	Age group 6 to < 12 years, oral isavuconazonium sulfate
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	7	9
Units: hours				

median (full range (min-max))	1.08 (1.03 to 1.35)	1.08 (1.02 to 1.22)	1.07 (1.02 to 1.20)	4.00 (1.98 to 6.08)
-------------------------------	---------------------	---------------------	---------------------	---------------------

End point values	Age group 12 to < 18 years, oral isavuconazonium sulfate			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: hours				
median (full range (min-max))	3.98 (3.05 to 8.03)			

Statistical analyses

No statistical analyses for this end point

Primary: Ctrough D7 iv and oral (Part 1 and Part 2)

End point title	Ctrough D7 iv and oral (Part 1 and Part 2) ^[11]
End point description:	Lowest concentration in plasma (Ctrough) of intravenous and oral isavuconazole reached before administration of the next dose, measured on Day7
End point type	Primary
End point timeframe:	D7
Notes:	[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses were planned for this endpoint.

End point values	Age group 1 to < 6 years, intravenous isavuconazonium sulfate	Age group 6 to < 12 years, intravenous isavuconazonium sulfate	Age group 12 to < 18 years, intraven. isavuconazonium sulfate	Age group 6 to < 12 years, oral isavuconazonium sulfate
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	8	9
Units: ng/ml				
arithmetic mean (standard deviation)	3320 (± 1710)	2970 (± 1680)	2730 (± 1140)	3970 (± 1840)

End point values	Age group 12 to < 18 years, oral isavuconazonium sulfate			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: ng/ml				

arithmetic mean (standard deviation)	3100 (± 1620)			
--------------------------------------	---------------	--	--	--

Statistical analyses

No statistical analyses for this end point

Primary: Ctrough D2 oral (Part 2 only)

End point title	Ctrough D2 oral (Part 2 only) ^{[12][13]}
End point description: Lowest concentration in plasma (Ctrough) of oral isavuconazole reached before administration of the next dose, measured on Day2	
End point type	Primary
End point timeframe: D2	

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint reports the Ctrough on Day2 of isavuconazole for the oral dose only.

End point values	Age group 6 to < 12 years, oral isavuconazonium sulfate	Age group 12 to < 18 years, oral isavuconazonium sulfate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: ng/ml				
arithmetic mean (standard deviation)	3690 (± 2070)	2550 (± 1420)		

Statistical analyses

No statistical analyses for this end point

Primary: Ctrough D5 oral (Part 2 only)

End point title	Ctrough D5 oral (Part 2 only) ^{[14][15]}
End point description: Lowest concentration in plasma (Ctrough) of oral isavuconazole reached before administration of the next dose, measured on Day5	
End point type	Primary
End point timeframe: D5	

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint reports the Ctrough on Day 5 of isavuconazole for the oral dose only.

End point values	Age group 6 to < 12 years, oral isavuconazonium sulfate	Age group 12 to < 18 years, oral isavuconazonium sulfate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	9		
Units: ng/ml				
arithmetic mean (standard deviation)	4400 (± 1750)	3250 (± 1420)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first administration of study medication up to 30 days after the last administration.

Adverse event reporting additional description:

Treatment-emergent adverse events and serious adverse events

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Age group 1 to < 6 years, intravenous isavuconazole
-----------------------	---

Reporting group description:

Age group 1 to < 6 years in the Part 1-study: intravenous infusion

Reporting group title	Age group 6 to < 12 years, intravenous isavuconazole
-----------------------	--

Reporting group description:

Age group 6 to < 12 years in the Part 1-study: intravenous infusion

Reporting group title	Age group 12 to < 18 years, intravenous isavuconazole
-----------------------	---

Reporting group description:

Age group 12 to < 18 years in the Part 1-study: intravenous infusion

Reporting group title	Age group 6 to < 12 years, oral isavuconazole
-----------------------	---

Reporting group description:

Age group 6 to < 12 years in the Part 2-study: oral capsule

Reporting group title	Age group 12 to < 18 years, oral isavuconazole
-----------------------	--

Reporting group description:

Age group 12 to < 18 years in the Part 2-study: oral capsule

Serious adverse events	Age group 1 to < 6 years, intravenous isavuconazole	Age group 6 to < 12 years, intravenous isavuconazole	Age group 12 to < 18 years, intravenous isavuconazole
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 9 (33.33%)	4 / 8 (50.00%)	5 / 10 (50.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolicism			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Mucosal inflammation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	2 / 8 (25.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Engraftment syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease in lung			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Oedema genital			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Electrocardiogram QT prolonged subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal incontinence			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	2 / 10 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysuria			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			

subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Cytarabine syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia bacterial			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Age group 6 to < 12 years, oral isavuconazole	Age group 12 to < 18 years, oral isavuconazole	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 9 (55.56%)	3 / 10 (30.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Embolism			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Mucosal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Engraftment syndrome			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft versus host disease			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft versus host disease in lung			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Oedema genital			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Electrocardiogram QT prolonged subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prothrombin time prolonged subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Tachycardia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal incontinence			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Cytarabine syndrome			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pneumonia bacterial			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Age group 1 to < 6 years, intravenous isavuconazole	Age group 6 to < 12 years, intravenous isavuconazole	Age group 12 to < 18 years, intravenous isavuconazole
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 9 (77.78%)	8 / 8 (100.00%)	10 / 10 (100.00%)
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	2

Hypertension subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 8 (25.00%) 3	0 / 10 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 2	1 / 10 (10.00%) 1
Venoocclusive disease subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Surgical and medical procedures Bone marrow transplant subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Central venous catheter removal subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 8 (25.00%) 2	0 / 10 (0.00%) 0
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	3 / 10 (30.00%) 3
Mucosal inflammation subjects affected / exposed occurrences (all)	4 / 9 (44.44%) 4	4 / 8 (50.00%) 5	2 / 10 (20.00%) 2
Pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Puncture site pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Pyrexia subjects affected / exposed occurrences (all)	4 / 9 (44.44%) 4	3 / 8 (37.50%) 3	4 / 10 (40.00%) 5
Immune system disorders Engraftment syndrome subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	2 / 10 (20.00%) 2

Graft versus host disease subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	1 / 10 (10.00%) 1
Graft versus host disease in gastrointestinal tract subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Graft versus host disease in liver subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Graft versus host disease in skin subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 8 (25.00%) 2	3 / 10 (30.00%) 3
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Reproductive system and breast disorders			
Acquired phimosis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Metrorrhagia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Testis discomfort subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1

Dyspnoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	2 / 9 (22.22%)	2 / 8 (25.00%)	1 / 10 (10.00%)
occurrences (all)	2	2	2
Haemoptysis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	1 / 9 (11.11%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Nasal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Tachypnoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Delirium			

subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Depressed mood			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Disorientation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dissociation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	2 / 9 (22.22%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Psychotic disorder			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Alanine aminotransferase increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood alkaline phosphatase decreased			

subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Blood bilirubin increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood urea increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Blood urine present			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood zinc decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Calcium ionised decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Carbon dioxide decreased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Cardiac murmur			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0

Colonoscopy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Crystal urine present			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Cystatin C abnormal			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Fibrin D dimer increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Haemoglobin decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	7
Neutrophil count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	2
Oxygen saturation decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Roseolovirus test positive subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Transaminases increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Urine analysis abnormal subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	0 / 8 (0.00%) 0	2 / 10 (20.00%) 9
Injury, poisoning and procedural complications			
Excoriation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Infusion related reaction subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 3	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Procedural nausea subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 3	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Procedural vomiting subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Scratch			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Cardiac disorders			
Atrial tachycardia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Conduction disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 9 (11.11%)	2 / 8 (25.00%)	2 / 10 (20.00%)
occurrences (all)	1	2	2
Nervous system disorders			
Burning sensation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dyskinesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	2 / 9 (22.22%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	2	1	0
Intention tremor			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Restless legs syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 3	1 / 8 (12.50%) 2	3 / 10 (30.00%) 11
Eosinophilia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Febrile neutropenia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	1 / 10 (10.00%) 1
Pancytopenia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 8	1 / 8 (12.50%) 3	2 / 10 (20.00%) 9
Ear and labyrinth disorders Dysacusis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Ear discomfort subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Eye disorders Dry eye subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 3	2 / 8 (25.00%) 3	2 / 10 (20.00%) 2
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Abdominal pain upper			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Aphthous ulcer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	3
Diarrhoea			
subjects affected / exposed	2 / 9 (22.22%)	3 / 8 (37.50%)	2 / 10 (20.00%)
occurrences (all)	9	4	2
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Gingival hypertrophy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Oral pain			

subjects affected / exposed	1 / 9 (11.11%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Perianal erythema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Proctalgia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	2
Papule			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences (all)	1	0	2
Pruritus allergic			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Rash erythematous			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash follicular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rash generalised			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rash pruritic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Skin irritation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin mass			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	3 / 8 (37.50%) 4	1 / 10 (10.00%) 1
Haematuria subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	1 / 10 (10.00%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	3 / 10 (30.00%) 3
Back pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	2 / 10 (20.00%) 2
Flank pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Myalgia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Pain in extremity subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	4 / 10 (40.00%) 4
Pain in jaw			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Infections and infestations			
BK virus infection			
subjects affected / exposed	1 / 9 (11.11%)	2 / 8 (25.00%)	0 / 10 (0.00%)
occurrences (all)	1	2	0
Bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	2
Cellulitis orbital			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile infection			
subjects affected / exposed	1 / 9 (11.11%)	1 / 8 (12.50%)	2 / 10 (20.00%)
occurrences (all)	1	1	2
Cystitis viral			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Cytomegalovirus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Device related infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epstein-Barr viraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epstein-Barr virus infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Escherichia bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0

Human herpesvirus 6 infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	2 / 10 (20.00%) 3
Lower respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Mastoiditis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Ophthalmic herpes simplex subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Rhinitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Sinusitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Staphylococcal bacteraemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Streptococcal bacteraemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Tracheitis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Vascular access site infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0

Viral haemorrhagic cystitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Fluid imbalance subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Fluid retention subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	1 / 10 (10.00%) 1
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	2 / 10 (20.00%) 3
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Hypermagnesaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Hypernatraemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 8 (12.50%) 1	0 / 10 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 3	0 / 8 (0.00%) 0	1 / 10 (10.00%) 1
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 8 (0.00%) 0	0 / 10 (0.00%) 0
Hypoglycaemia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 8 (12.50%)	3 / 10 (30.00%)
occurrences (all)	1	1	3
Hyponatraemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Hypophosphataemia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 8 (12.50%)	0 / 10 (0.00%)
occurrences (all)	2	1	0
Malnutrition			
subjects affected / exposed	0 / 9 (0.00%)	0 / 8 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Age group 6 to < 12 years, oral isavuconazole	Age group 12 to < 18 years, oral isavuconazole	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	9 / 10 (90.00%)	
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Hypertension			
subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Venoocclusive disease			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 2	
Surgical and medical procedures			
Bone marrow transplant			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Central venous catheter removal			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Mucosal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	3	
Pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Puncture site pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	3 / 9 (33.33%)	2 / 10 (20.00%)	
occurrences (all)	4	3	
Immune system disorders			
Engraftment syndrome			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Graft versus host disease			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Graft versus host disease in gastrointestinal tract			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Graft versus host disease in liver			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Graft versus host disease in skin subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Reproductive system and breast disorders			
Acquired phimosis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Metrorrhagia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Testis discomfort subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Cough subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Epistaxis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Haemoptysis			

subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Hypoxia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Nasal congestion			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Nasal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	2 / 9 (22.22%)	0 / 10 (0.00%)	
occurrences (all)	3	0	
Pleural effusion			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Pleuritic pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Tachypnoea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Delirium			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Depressed mood			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Depression			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

Disorientation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Dissociation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Insomnia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Irritability			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Psychotic disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Alanine aminotransferase increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Blood alkaline phosphatase decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Blood bilirubin increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Blood creatinine increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Blood fibrinogen decreased			

subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Blood fibrinogen increased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Blood lactate dehydrogenase increased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Blood urea increased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Blood urine present		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Blood zinc decreased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Calcium ionised decreased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Carbon dioxide decreased		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Cardiac murmur		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Colonoscopy		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Crystal urine present		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Cystatin C abnormal		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0

Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Fibrin D dimer increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Oxygen saturation decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0
Roseolovirus test positive subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0
Transaminases increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0

Urine analysis abnormal subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 10 (20.00%) 2	
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Injury, poisoning and procedural complications			
Excoriation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Procedural nausea subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Procedural pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Procedural vomiting subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Scratch subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Cardiac disorders			
Atrial tachycardia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Conduction disorder subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Tachycardia			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Nervous system disorders			
Burning sensation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Dizziness			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Dyskinesia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Headache			
subjects affected / exposed	2 / 9 (22.22%)	1 / 10 (10.00%)	
occurrences (all)	3	1	
Intention tremor			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Restless legs syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Tremor			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 9 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Eosinophilia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Febrile neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Neutropenia			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Pancytopenia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Ear and labyrinth disorders Dysacusis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Ear discomfort subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Eye disorders Dry eye subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	2 / 10 (20.00%) 2	
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Anorectal discomfort subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Aphthous ulcer subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Constipation			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Diarrhoea		
subjects affected / exposed	2 / 9 (22.22%)	1 / 10 (10.00%)
occurrences (all)	2	1
Flatulence		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Gastritis		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Gastrointestinal haemorrhage		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Gingival hypertrophy		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Lip swelling		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Mouth ulceration		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Nausea		
subjects affected / exposed	1 / 9 (11.11%)	2 / 10 (20.00%)
occurrences (all)	1	2
Oral pain		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Perianal erythema		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Proctalgia		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Stomatitis		

subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	2 / 9 (22.22%)	4 / 10 (40.00%)	
occurrences (all)	4	5	
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Blister			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Papule			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Pruritus allergic			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Pruritus generalised			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	1 / 9 (11.11%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Rash erythematous			

subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Rash follicular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Rash generalised			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Rash macular			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Rash maculo-papular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Rash pruritic			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Skin disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Skin irritation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Skin lesion			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Skin mass			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Urticaria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	

Haematuria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 2	
Back pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Flank pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Muscle spasms subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Pain in jaw subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Infections and infestations			
BK virus infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Bacteraemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Cellulitis orbital			

subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Clostridium difficile infection		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Cystitis viral		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Cytomegalovirus infection		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Device related infection		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Epstein-Barr viraemia		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Epstein-Barr virus infection		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Escherichia bacteraemia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Gastroenteritis		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Human herpesvirus 6 infection		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Lower respiratory tract infection viral		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Mastoiditis		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Ophthalmic herpes simplex		

subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Oral candidiasis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Rhinitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Sinusitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Streptococcal bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Tracheitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Vascular access site infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Viral haemorrhagic cystitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Fluid imbalance			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	

Fluid retention		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Hyperglycaemia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Hyperkalaemia		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Hypermagnesaemia		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Hypernatraemia		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Hyperphosphataemia		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Hypoalbuminaemia		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Hypocalcaemia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Hypoglycaemia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Hypokalaemia		
subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)
occurrences (all)	1	1
Hypomagnesaemia		
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0
Hyponatraemia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1

Hypophosphataemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Malnutrition			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 August 2017	Changes to the protocol included changing the lower age limit for cohort 1 from 2 years of age to 1 year of age, and adding a dose rationale for subjects 1 to 2 years of age.
26 April 2018	Changes to the protocol included the addition of oral cohorts 4 and 5 to constitute part 2 of the study, including rationale, dosing regimen, and pharmacokinetics sampling profile for subjects in the oral cohorts. All subjects in cohorts 1 through 3 were administered only intravenous drug and thus were unaffected by the changes made in this Amendment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported